Zobrazeno 1 - 10
of 308
pro vyhledávání: '"Hiroshi Nomoto"'
Autor:
Yuki Oe, Hiroshi Nomoto, Kyu Yong Cho, Kei Yokozeki, Tsubasa Ono, Aika Miya, Hiraku Kameda, Akinobu Nakamura, Yoshiaki Arimura, Tatsuya Atsumi
Publikováno v:
BMC Endocrine Disorders, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Oral semaglutide in older subjects with type 2 diabetes was as effective as in younger subjects, according to phase 3 clinical trials. However, its efficacy can be limited in very aged population, due to the presence of impaired c
Externí odkaz:
https://doaj.org/article/47768c8012034b3c807844e9992d4bf5
Autor:
Rimi Izumihara, Hiroshi Nomoto, Kenichi Kito, Yuki Yamauchi, Kazuno Omori, Yui Shibayama, Shingo Yanagiya, Aika Miya, Hiraku Kameda, Kyu Yong Cho, So Nagai, Ichiro Sakuma, Akinobu Nakamura, Tatsuya Atsumi
Publikováno v:
Diabetes & Metabolism Journal, Vol 48, Iss 3, Pp 473-481 (2024)
Background Fibrates have renal toxicity limiting their use in subjects with chronic kidney disease (CKD). However, pemafibrate has fewer toxic effects on renal function. In the present analysis, we evaluated the effects of pemafibrate on the renal fu
Externí odkaz:
https://doaj.org/article/434fc40dd96546bfba539ebd70216bbd
Autor:
Sho Furusawa, Hiroshi Nomoto, Chiho Oba-Yamamoto, Jun Takeuchi, Miki Ito, Hiroyoshi Kurihara, Shin Aoki, Aika Miya, Hiraku Kameda, Akinobu Nakamura, Tatsuya Atsumi
Publikováno v:
Endocrine Journal, Vol 71, Iss 6, Pp 603-616 (2024)
Oral semaglutide has potent anti-hyperglycemic efficacy in phase III trials. However, the complicated dosing instructions hamper to use this drug; therefore, we evaluated the efficacy and safety of oral semaglutide in subjects with type 2 diabetes in
Externí odkaz:
https://doaj.org/article/248049dd9a5c4e8c94aa8491ee12b524
Publikováno v:
Biochemistry and Biophysics Reports, Vol 38, Iss , Pp 101702- (2024)
ProNGF (nerve growth factor) is a precursor of NGF and a signaling peptide exerting opposite effects on neuronal cells, i.e., apoptotic or neuritogenic. The conflicting biological activity of proNGF depends on the relative levels of two membrane rece
Externí odkaz:
https://doaj.org/article/7e766c5b0f2c4b238e12f38f7eff565d
Publikováno v:
Endocrine Journal, Vol 71, Iss 4, Pp 403-408 (2024)
The proinsulin-to-C-peptide (PI:C) ratio is an index applied during the early stage of pancreatic β-cell dysfunction. The aim of this study was to identify the characteristics associated with the PI:C ratio to discuss pancreatic β-cell dysfunction
Externí odkaz:
https://doaj.org/article/5fa4abb554d5466ab650ee1e4a4f32f9
Autor:
Akinobu Nakamura, Aika Miya, Yuka Suzuki, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, So Nagai, Tatsuya Atsumi
Publikováno v:
Endocrine Journal, Vol 71, Iss 2, Pp 193-197 (2023)
The post-hoc study, derived from our previous prospective observational study, investigated the association between fasting serum proinsulin levels and hepatic steatosis in people with type 2 diabetes. The severity of hepatic steatosis was assessed u
Externí odkaz:
https://doaj.org/article/4c60741ec65042deb777aa96c3cc05bf
Autor:
Hiroshi Nomoto, Kenichi Kito, Hiroshi Iesaka, Takahisa Handa, Shingo Yanagiya, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Jun Takeuchi, So Nagai, Ichiro Sakuma, Akinobu Nakamura, Tatsuya Atsumi
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 15, Iss 1, Pp 1-6 (2023)
Abstract Background Pemafibrate has been reported to ameliorate lipid profiles and liver dysfunction. However, which patients derive benefit from the hepatoprotective effects of pemafibrate is unclear. Methods We conducted a sub-analysis of the PARM-
Externí odkaz:
https://doaj.org/article/5bb4852fbbde4581be2db141350d4fa6
Autor:
Yuki Yamauchi, Akinobu Nakamura, Takashi Yokota, Kiyohiko Takahashi, Shinichiro Kawata, Kazuhisa Tsuchida, Kazuno Omori, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, Toshihisa Anzai, Shinya Tanaka, Yasuo Terauchi, Hideaki Miyoshi, Tatsuya Atsumi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-12 (2022)
Abstract We aimed to determine the mechanism by which the sodium glucose co-transporter 2 inhibitor, luseogliflozin, preserves pancreatic beta-cell mass and function in db/db mice. Six-week-old db/db mice were fed to standard chow or standard chow co
Externí odkaz:
https://doaj.org/article/c1a2036c306a49faa4f57882e630c63f
Autor:
Kyu Yong Cho, Tatsuya Atsumi, Hiroshi Nomoto, Jun Takeuchi, So Nagai, Akinobu Nakamura, Hideaki Miyoshi, Shinji Taneda, Aika Miya, Hiraku Kameda, Akihiro Takahashi, Hiroyoshi Kurihara
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 10, Iss 6 (2022)
Introduction Imeglimin is a novel anti-hyperglycemic drug that improves both insulin resistance and insulin secretion. The effects of imeglimin on glycemic control were confirmed in phase III clinical trials, but little is known about its effectivene
Externí odkaz:
https://doaj.org/article/97c4b01d827247b1bef0e3e070c8f9cd
Autor:
Tomonori Sekizaki, Hiraku Kameda, Hiroshi Nomoto, Kyu Yong Cho, Akinobu Nakamura, Kiyohiko Takahashi, Arina Miyoshi, Norio Wada, Jun Takeuchi, So Nagai, Hideaki Miyoshi, Tatsuya Atsumi
Publikováno v:
Journal of Diabetes Investigation, Vol 12, Iss 11, Pp 1978-1982 (2021)
Abstract Dipeptidyl peptidase‐4 (DPP‐4), namely CD26, is expressed on the surface of immune cells, suggesting that inhibition of DPP‐4 might affect the immune system. The current multicenter observational case–control study was carried out to
Externí odkaz:
https://doaj.org/article/94be6223aef645b6a02a091f2fdbd1b7